Position in IDXX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$13,108,882
-$1,830,087 QoQ
Shares Held
24,901
-6.3% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#247
of 1,286 holders
Holding Since
Dec 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in IDXX Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Tredje AP-fonden holds $193,224,532 across 10 Diagnostics & Research names. IDXX ranks #6 (6.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
115,995 | $58,155,253 | |
| 2 | DHR |
Danaher Corp /De/
|
190,220 | $36,233,105 | |
| 3 | NTRA |
Natera, Inc.
|
68,178 | $18,506,918 | |
| 4 | ILMN |
Illumina, Inc.
|
100,901 | $17,741,422 | |
| 5 | A |
Agilent Technologies, Inc.
|
108,000 | $14,345,640 | |
| 6 | IDXX |
Idexx Laboratories Inc /De
This page
|
24,901 | $13,108,882 | |
| 7 | WAT |
Waters Corp /De/
|
32,971 | $12,365,443 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
62,663 | $12,107,744 |
All Filings in IDXX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,108,882 | 24,901 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $14,938,969 | 26,587 | Shares | Sole | 2026-05-12 | |
| 2022-09-30 | $2,671,560 | 8,200 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $2,875,986 | 8,200 | Shares | Sole | 2022-08-11 | |
| 2022-03-31 | $4,485,892 | 8,200 | Shares | Sole | 2022-05-09 | |
| 2021-12-31 | $5,399,372 | 8,200 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $3,607,020 | 5,800 | Shares | Sole | 2021-11-10 | |
| 2021-06-30 | $3,031,440 | 4,800 | Shares | Sole | 2021-08-06 | |
| 2021-03-31 | $2,348,688 | 4,800 | Shares | Sole | 2021-05-10 | |
| 2020-12-31 | $2,399,376 | 4,800 | Shares | Sole | 2021-02-12 | |
| No filing history on record for this holder in this stock. | ||||||